🔴 GRAIL is trading 11.37% down today after adjusted EBITDA losses widened

GRAIL is trading 11.37% down now at $65.75 after investors reacted negatively to its August 5 earnings and wider adjusted EBITDA losses.

• Revenue reached $44.7 million, beating estimates, but adjusted EBITDA losses widened 15% year over year to $90.3 million; lower average selling prices pressured growth.
• The upcoming fall FDA advisory committee, timing uncertainty, and the company’s unmet NHS-Galleri primary endpoint are adding risk despite strong test-volume growth.